Neural circuitry underlying the central hypertensive action of nesfatin-1: Melanocortins, corticotropin-releasing hormone, and oxytocin

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 306, Issue 10, 2014, Pages

  Yosten, Gina L C ^a   Samson, Willis K ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Central control of blood pressure; CRH; Melanocortin; Nesfatin 1; Oxytocin

Indexed keywords

ADIPOCYTOKINE; ALPHA INTERMEDIN; ANOREXIGENIC AGENT; ASTRESSIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; HYPERTENSIVE AGENT; MELANOCORTIN; NESFATIN 1; OXYTOCIN; OXYTOCIN[2 PHENYLALANINE 8 ORNITHINE]; STRESS HORMONE; UNCLASSIFIED DRUG; VASOTOCIN DERIVATIVE;

ANIMAL EXPERIMENT; APPETITE; ARTICLE; CARDIOVASCULAR FUNCTION; CELL SUBPOPULATION; CONTROLLED STUDY; FOOD INTAKE; HORMONE RELEASE; MEAN ARTERIAL PRESSURE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT;

CENTRAL CONTROL OF BLOOD PRESSURE; CRH; MELANOCORTIN; NESFATIN-1; OXYTOCIN;

ALPHA-MSH; ANIMALS; BLOOD PRESSURE; CALCIUM-BINDING PROTEINS; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; HORMONES; HYPERTENSION; MALE; MELANOCORTINS; MELANOCYTE-STIMULATING HORMONES; NERVE NET; NERVE TISSUE PROTEINS; OXYTOCIN; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, OXYTOCIN; VASOTOCIN;

EID: 84900525281     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00396.2013     Document Type: Article

References (47)

1. Arima H, Aguilera G. Vasopressin and oxytocin neurons of hypothalamic supraoptic and paraventricular nuclei co-express mRNA for type-1 and type-2 corticotropin-releasing hormone receptors. J Neuroendocrinol 12: 833-842, 2000.
2. Bariohay B, Roux J, Tardivel C, Trouslard J, Jean A, Lebrun B. Brain-derived neurotrophic factor/tropomyosin-related kinase receptor type B signaling is a downstream effector of the brainstem melanocortin system in food intake control. Endocrinology 150: 2646-2653, 2009.
3. Brailoiu GC, Dun SL, Brailoiu E, Inan S, Yang J, Chang JK, Dun NJ. Nesfatin-1 distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 148: 5088-5094, 2007.
4. Cheung CC, Clifton DK, Steiner RA. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 138: 4489-4492, 1997.
5. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci 8: 571-578, 2005.
6. Dabrowska J, Hazra R, Ahern TH, Guo JD, McDonald AJ, Mascagni F, Muller JF, Young LJ, Rainnie DG. Neuroanatomical evidence for reciprocal regulation of the corticotropin-releasing factor and oxytocin systems in the hypothalamus and the bed bucleus of the stria terminalis of the rat: implications for balancing stress and affect. Psychoneuroendocinology 36: 1312-1326, 2001.
7. Da Silva AA, do Carmo JM, Hall JE. Role of leptin and central nervous system melanocortins in obesity hypertension. Curr Opin Nephrol Hypertens 2: 135-140, 2013.
8. Enriori PJ, Evans AE, Sinnayah P, Jobst EE, Tonelli-Lemons L, Billes SK, Glavas MM, Grayson BE, Perello M, Nillni EA, Grove KL, Cowley MA. Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons. Cell Metab 5: 181-194, 2007.
9. Foo KS, Brauner H, Ostenson CG, Broberger C. Nucleobindin-2/ nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol 204: 255-263, 2010.
10. Foo K, Brismar H, Broberger C. Distribution and neuropeptide coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience 156: 563-579, 2008.
11. Goebel-Stengel M, Wang L, Stengel A, Tache Y. Localization of nesfatin-1 neurons in mouse brain and functional implication. Brain Res 1396: 20-34, 2009.
12. Jhamandas JH, MacTavish D. Central administration of Neuropeptide FF causes activation of oxytocin paraventricular hypothalamic neurons that project to brainstem. J Neuroendocrinol 15: 24-32, 2003.
13. Konczol K, Bodnar I, Zelena Z, Pinter O, Papp RS, Palkovits M, Najy GM, Toth ZE. Nesfatin-1/NUCB2 may participate in the activation of the hypothalamic-pituitary-adrenal axis in rats. Neurochem Int 57: 189-197, 2010.
14. Kublaoui BM, Gemelli T, Tolson KP, Wang Y, Zinn AR. Oxytocin deficiency mediates hyperphagic obesity of Sim1 haploinsufficient mice. Mol Endocrinol 22: 1723-1734, 2008.
15. Lu XY, Barsh GS, Akil H, Watson SJ. Interaction between alphamelanocyte stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-pituitary-adrenal responses. J Neurosci 23: 7863-7872, 2003.
16. Maejima Y, Sedbazar U, Suyama S, Kohno D, Takano E, Yoshida N, Koike M, Uchiyama Y, Fujiwara K, Yashiro T, Horvath TL, Dietrich MO, Tanaka S, Dezaki K, Oh-IS, Hashimoto K, Shimizu H, Nakata M, Mori M, Yada T. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab 10: 355-365, 2009.
17. Merali Z, Cayer C, Kent P, Anisman H. Nesfatin-1 increases anxietyand fear-behavior in the rat. Psychopharmacology 201: 115-123, 2008.
18. Mimee A, Smith PM, Ferguson AV. Nesfatin-1 influences the excitability of neurons in the nucleus of the solitary tract and regulates cardiovascular function. Am J Physiol Regul Integr Comp Physiol 302: R1297-R1304, 2012.
19. Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 207: 928-934, 2008.
20. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 443: 709-712, 2006.
21. Olson BR, Drutarosky MD, Stricker EM, Verbalis JG. Brain oxytocin receptors mediate corticotropin-releasing hormone-induced anorexia. Am J Physiol Regul Integr Comp Physiol 260: R448-R452, 1991.
22. Pan W, Hsuchou H, Kastin AJ. Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides 28: 2223-2228, 2007.
23. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates (Compact) (3rd ed). San Diego, CA. Academic, 1997.
24. Price CJ, Samson WK, Ferguson AV. Nesfatin-1 inhibits NPY neurons in the arcuate nucleus. Brain Res 1230: 99-106, 2008.
25. Price TO, Samson WK, Niehoff ML, Banks WA. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 28: 2372-2381, 2007.
26. Rahmouni K, Haynes WG. Leptin and the cardiovascular system. Recent Prog Horm Res 59: 225-244, 2004.
27. Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 54: 2012-2018, 2005.
28. Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK, Randeva HS. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 151: 3169-3180, 2010.
29. Sabatier N, Caqineau C, Dayaithi G, Bull P, Douglas AJ, Guan XMM, Jiang M, Van der Ploeg L, Leng G. Alpha-melanocyte-stimulating hormone stimulates oxytocin release from dendrites of hypothalamic neurons while inhibiting oxytocin release from their terminals in the neurohypophysis. J Neurosci 23: 10351-10358, 2003.
30. Segal-Lieberman G, Rosenthal T. Animal models in obesity and hypertension. Curr Hypertens Rep 15: 190-193, 2013.
31. Shimizu H, Oh-IS, Hashimoto K, Nakata M, Yamamoto S, Yoshida N, Eguchi H, Kato I, Inoue K, Satoh T, Okada S, Yamada M, Yada T, Mori M. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 150: 662-671, 2009.
32. Sinha MK, Opentanova I, Ohannesian JP, Kolaczynski JW, Heiman ML, Hale J, Becker GW, Bowsher RR, Stephens TW, Caro JF. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin Invest 98: 1277-1282, 1996.
33. Stengel A, Goebel M, Wang L, Rivier J, Kobelt P, Moennikes H, Lambrecht NWG, Tache Y. Central nesfatin-1 reduces dark-phase food intake and gastric emptying: differential role of corticotropin-releasingfactor2 receptor. Endocrinology 150: 4911-4919, 2009.
34. Stengel A, Goebel M, Yakubov I, Wang L, Witcher D, Coskun T, Tache Y, Sachs G, Lambrecht NW. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 150: 232-238, 2009.
35. Tan BK, Hallschmid M, Kern W, Lehnert H, Randeva HS. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/ NUCB-2, in obese human: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab 96: E669-E673, 2011.
36. Tanida M, Mori M. Nesfatin-1 stimulates renal sympathetic nerve activity in rats. Neuroreport 22: 309-312, 2011.
37. Tolson KP, Gemelli T, Gautron L, Elmquist JK, Zinn AR, Kublaoui BM. Postnatal Sim1 deficiency causes hyperphagic obesity and reduced Mc4r and oxytocin expression. J Neurosci 30: 3803-3812, 2010.
38. Trombetta IC, Batalha LT, Urbana M, Rondon PB, Laterza MC, Kuniyoshi FHS, Gowdak MMG, Barretto ACP, Halpern A, Villares SMF, Negrao CE. Weight loss improves neurovascular and muscle metaboreflex control in obesity. Am J Physiol Heart Circ Physiol 285: H974-H982, 2003.
39. Tuck ML. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 19, Suppl 1: 167-177, 1992.
40. Vaccari C, Lolait SJ, Ostrowski NL. Comparative distribution of vasopressin V1b and oxytocin receptor messaneger ribonucleic acids in brain. Endocrinology 139: 5014-5033, 1998.
41. Yoshida N, Maejima Y, Yamada M, Osaki A, Oh-IS, Ariyama Y, Takahashi H, Okada S, Hashimoto K, Kurashina T, Onaka T, Dezaki K, Nakata M, Mori M, Yada T. Stressor-responsive central nesfatin-1 activates corticotropin releasing hormone, noradrenaline and serotonin neurons and evokes hypothalamo-pituiatry-adrenal axis. Aging 2: 775-784, 2010.
42. Yoshida M, Takayanagi Y, Inoue K, Kimura T, Young LJ, Onaka T, Nishimori K. Evidence that oxytocin exerts anxiolytic effects via oxytocin receptors expressed in serotonergic neurons in mice. J Neurosci 29: 2259-2271, 2009.
43. Yosten GLC, Samson WK. Nesfatin-1 exerts cardiovascular effects in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol 297: R330-R336, 2009.
44. Yosten GLC, Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am J Physiol Regul Integr Comp Physiol 298: R1642-R1647, 2010.
45. Zar JH. Biostatistical Analysis (2nd ed.). Englewood Cliffs, NJ. Prentice Hall, 1984.
46. Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 120: 91-95, 2012.
47. Zegers D, Beckers S, Mertens IL, Van Gaal LF, Van Hul W. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab 103: 282-286, 2011.